Details About Generic Salt ::  Nicardip

Main Medicine Class:: Calcium channel blocker   

(NYE-CAR-dih-peen HIGH-droe-KLOR-ide)
Cardene
Capsules: 20 mg, 30 mg
Cardene I.V.
Injection: 2.5 mg/mL
Cardene SR
Capsules, sustained-release: 30 mg, 45 mg, 60 mg
Class: Calcium channel blocker

 

Drugs Class ::

 Action Inhibits movement of calcium ions across cell membrane in systemic and coronary vascular smooth muscle and myocardium.

Indications for Drugs ::

 Indications Treatment of chronic stable (effort-associated) angina (immediate-release capsules); management of hypertension (immediate- and sustained-release capsules; IV when oral therapy not feasible or desireable).

Drug Dose ::

 Route/Dosage

Angina (Immediate-Release Only)

ADULTS: PO Usual initial dose 20 mg tid (range, 20 to 40 mg tid).

Hypertension

ADULTS: PO Immediate-release: Usual dose 20 mg tid (range, 20 to 40 mg tid). Sustained-release: Start with 30 mg bid (range, 30 to 60 mg bid). IV Individualize dosage based on severity of hypertension and response of patient during dosing.

Contraindication ::

 Contraindications Sick sinus syndrome; second- or third-degree atrioventricular (AV) block except with functioning pacemaker; advanced aortic stenosis.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Antiplatelet effects: Calcium channel blockers may inhibit platelet function. Beta-blocker withdrawal: Patients withdrawn from beta-blockers while taking nicardipine may experience increased angina. Gradually taper beta-blocker dose. CHF: Use drug with caution in patients with CHF. Hepatic impairment: Adjust dosage and use drug with caution in patients with impaired hepatic function or reduced hepatic blood flow. Increased angina: Occasionally patients have increased frequency, duration, or severity of angina on starting or increasing dose. Renal impairment: Adjust dose in patients with renal dysfunction. Withdrawal: Abrupt withdrawal may cause increased frequency and duration of angina.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Peripheral edema; palpitations; AV block; MI; angina; tachycardia; abnormal ECG. CNS: Dizziness; lightheadedness; asthenia; psychiatric disturbances; headache; paresthesia; somnolence; weakness. DERM: Rash. GI: Nausea; abdominal discomfort; cramps; dyspepsia; dry mouth; thirst. OTHER: Flushing; allergic reaction; myalgia.

Drug Mode of Action ::  

 Action Inhibits movement of calcium ions across cell membrane in systemic and coronary vascular smooth muscle and myocardium.

Drug Interactions ::

 Interactions

Cyclosporine: May cause increased cyclosporine levels with possible toxicity. Other hypertensive agents: May have additive effects.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Evaluate cardiac, hepatic, renal, and thyroid function.
  • Obtain baseline vital signs and monitor 1 to 2 hr and 8 hr after administration of immediate-release product and 2 to 4 hr and at end of dosing interval if sustained-release product is used.
  • Obtain baseline ECG and any follow-up ECGs as ordered by health care provider.
  • Assess for edema, dizziness, headache, sore throat, renal changes, palpitations, liver dysfunction, or flushing.
  • If patient has history of liver, renal, or cardiac dysfunction, monitor patient closely for changes from baseline.
  • If there are any changes from baseline assessment, notify health care provider.
  • If used to treat angina, monitor frequency of anginal episodes and consumption of sublingual nitroglycerin.
OVERDOSAGE: SIGNS & SYMPTOMS
  Nausea, weakness, dizziness, drowsiness, confusion, slurred speech, marked and prolonged hypotension, bradycardia, functional rhythms, second- or third-degree AV block, palpitations, flushing, nervousness, vomiting

Drug Storage/Management ::

 Administration/Storage

  • Administer without regard to meals. Avoid giving with high-fat meals.
  • If patient is taking sustained-released capsules, instruct patient to swallow capsule whole and not to chew, divide, or crush.
  • If stopping medication, taper dose slowly. Stopping drug quickly could result in immediate angina.
  • If patient has history of liver or renal disease, start with low doses and titrate.
  • Do not increase dose for minimum of 3 days after starting medication or dose changes.
  • When converting from immediate-release form to sustained-release form, note that dosage may differ.
  • Store at controlled room temperature (56° to 86°F) in tight, light-resistant container.

Drug Notes ::

 Patient/Family Education

  • Instruct patient to swallow sustained-release capsules whole and not to crush or chew.
  • Caution patient that increased angina may occur initially when starting, changing dose, or stopping medication.
  • Advise patient not to stop taking drug abruptly.
  • Instruct patient to report the following symptoms to health care provider: any unusual bleeding, bruising, rash, palpitations, irregular heartbeat, shortness of breath, nausea, change in angina, constipation, changes in gums, dizziness, or swelling in hands or feet.
  • Advise patient that drug may cause dizziness or drowsiness and to use caution while driving or performing other tasks requiring mental alertness.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.